Why We Do Not Recommend That Women With Breast Cancer Receive Adjuvant Treatment With a CDK4/6 Inhibitor
- PMID: 40228181
- DOI: 10.1200/JCO-24-02683
Why We Do Not Recommend That Women With Breast Cancer Receive Adjuvant Treatment With a CDK4/6 Inhibitor
Comment in
-
Balancing evidence and individualization in adjuvant CDK4/6 therapy.Transl Cancer Res. 2025 Aug 31;14(8):4479-4481. doi: 10.21037/tcr-2025-879. Epub 2025 Aug 16. Transl Cancer Res. 2025. PMID: 40950694 Free PMC article. No abstract available.
LinkOut - more resources
Full Text Sources